Retifanlimab Wins Upfront Indication for Anal Cancer ...Middle East

Medscape - News
Retifanlimab Wins Upfront Indication for Anal Cancer
The anti-PD-1 antibody was approved as first-line treatment for locally recurrent or metastatic squamous cell anal carcinoma. Medscape Medical News

Hence then, the article about retifanlimab wins upfront indication for anal cancer was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Retifanlimab Wins Upfront Indication for Anal Cancer )

Apple Storegoogle play

Last updated :

Also on site :